6DECEMBER - 2021TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comThe introduction of new therapeutics such as biologics, cell and gene therapies, antibody-drug conjugates, and cytotoxic/Highly Potent Active Pharmaceutical Ingredients (HPAPIs) has added to the complexity of drug development. Despite a large amount of money spent on research and development, the return on investment has been declining for some time. As biologics have grown in popularity, the number of new biologics being developed has increased. To help overcome critical challenges and achieve greater efficiencies across the drug development continuum, large and small drug developers are partnering with Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) earlier in the development process.Many pharma and biopharma trends are contributing to increased outsourcing of R&D activities, in addition to reducing drug development timelines and costs. Increasingly complex small molecules and biologics, which necessitate highly specific drug technologies and expertise to handle highly potent and targeted therapies, such as Cell and Gene therapies, Cytotoxic/HPAPIs, and Antibody-drug conjugates(ADCs), are among them. Many pharmaceutical companies are currently partnering with CDMOs earlier in the drug development process to save money and reduce product development time.Our editorial board at Pharma Tech Outlookhas analyzed the most popular trends of the year to assist industry leaders in steering in the right direction when adopting Pharma Outsourcing solutions and services. We have filtered out the companies that genuinely set themselves a league apart, and strive to not only outperform the rest of the pack but also solve pressing challenges prevailing in the industry. Please, let us know your thoughts.Saving Lives by Reducing Drug Development TimeTECH OUTLOOKTECH OUTLOOKCopyright © 2021 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.DECEMBER - 16 - 2021, Vol 07 - Issue 19 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerJaxon JaseEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:David Parker
< Page 5 | Page 7 >